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hemoptysis in an elderly patient with inoperable lung cancerAlessandro Baisi, MD,a Federico Raveglia, MD,a Matilde De Simone, MD, PhD,b and
Ugo Cioffi, MD, PhD,b Milan, ItalySurgical resection remains the standard therapeutic treat-
ment for patients with resectable non–small cell lung cancer
and for selected patients with limited pulmonary metastases
from extrathoracic tumors, even if only a small number of
patients are suitable for potentially curative resection.1,2 Per-
cutaneous image-guided radiofrequency ablation (RFA) is
a minimally invasive therapeutic option that has been suc-
cessfully applied to local control of tumors in different or-
gans including the lung.3,4 This technique has recently
been recognized as the primary therapy in patients who are
not candidates for limited surgery or radiotherapy and can
be used to treat recurrent lesions.4 The procedure is well tol-
erated and the complication rate is acceptable even when
considering the treatment of large masses.4,5 We report
a case of an elderly patient with advanced lung cancer lead-
ing to severe and recurring hemoptysis that was successfully
treated with RFA.CLINICAL SUMMARY
An 82-year-old woman was referred to our department
with right lung cancer complicated by severe and recurring
hemoptysis necessitating repeated blood transfusions. The
tumor was 63 6 cm in size, located in the peripheral paren-chyma of the lower lobe, with pathologic hilar and medias-
tinal lymph nodes. Three months earlier, she had been
excluded from both surgery and medical treatment owing
to the tumor stage (IIIB) and respiratory and cardiac comor-
bidities. Several bronchoscopic examinations were per-
formed showing blood in the airways without any evident
endobronchial source of the bleeding. Endobronchial cauter-
ization was unfeasible to control the hemoptysis because
there was no evident endobronchial source of the bleeding.
No bronchial or pulmonary vessels supplying the mass
were identified in an arteriogram, and embolization was
also impossible. In the hope of controlling the bleeding by
sclerosing the tumor, we attempted a percutaneous RFA, de-
spite the size of the mass and the tumor stage. The procedure
was performed under a nonenhanced computed tomographic
(CT) scan by RF 3000 Radiofrequency Generator with
a 16-gauge, 15-cm long, 4.0-cm array diameter LeVeen
CoAssess Electrode (Radiotherapeutics, Boston Scientific
Corporation, Natick, Mass), starting from 30 up to 160 watts
(Figure 1) and repeated more in depth in the mass starting
from 30 up to 120 watts (Figure 2). The hemoptysis was suc-
cessfully controlled after the procedure. A minimal pleural
effusion without pneumothorax occurred. At the 6-month
follow-up, the patient was free from bleeding and the mass
was reduced to 5 3 5 cm. One year after the procedure the
patient died of distant metastases.DISCUSSION
The safety and feasibility of percutaneous RFA for un-
resectable lung cancers have now been considered by sev-
eral authors.1,2,5 Survival time and efficacy of the
procedure are significantly longer in patients with com-
pletely ablative tumors.2 Tissue ablation adequacy dependsgery c November 2010
FIGURE 1. Nonenhanced CT scan showing a 63 6 cm lung cancer on the
inferior right lobe. A multitined expandable array was inserted under CT
guide and the procedure was performed starting from 30 up to 160 watts
and repeated from 30 up to 120 watts. CT, Computed tomographic.
FIGURE 2. Nonenhanced CT scan: the array was reinserted more in depth
in the mass and the procedure was repeated. CT, Computed tomographic.
Brief Technique Reportson the extent of necrosis that is in inverse proportion to the
tumor size. Tumors of 3 cm or less guarantee complete ne-
crosis and better survival.4 These findings indicate that
RFA may provide a promising alternative therapy in the
management of lung tumors, especially for patients not
amenable to surgery.6 Furthermore, this technique allows
ablation of the tumor tissue without damaging the sur-
rounding normal parenchyma2 so that this procedure can
be performed also in patients with severe lung or cardio-
vascular comorbidities.6
Our patient had a cancerous mass, 6 cm in size, in the right
lung that was complicated by a severe life-threatening he-
moptysis causing anemia and repeated blood transfusions.
As performing laser coagulation and arterial embolization
was impossible, we decided to perform RFA despite the tu-
mor size of 6 cm to control the bleeding. Our patient received
RFA of the tumor by the standard technique and the hemop-
tysis was successfully controlled immediately after the
procedure. Furthermore, at the 3- and 6-month follow-up
examinations with CT scan, the lesion appeared stable and
had reduced to 5 cm in size. It is important to underlineThe Journal of Thoracic and Carthat we did not observe major complications after the
procedure.
Our experience shows that RFA can be helpful in the man-
agement of hemoptysis complicating lung cancer that is not
suitable for other treatments such as endobronchial coagula-
tion or embolization. We suggest a further indication of this
technique in the management of complicated unresectable
non–small cell lung cancer.References
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